Company Profile
ProMIS Neurosciences Stock Price, News & Catalysts
- Ticker:
- PMN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada and listed in the U
Stock performance
14.66 USD (-1.35%)
Close
Last updated: August 17, 2026
91M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, PMN closed down 1.35% at $14.66. No new same-company headline was identified in the current news window.
Company overview
Misfolded Protein Therapeutics
ProMIS Neurosciences develops antibodies that selectively recognize toxic misfolded protein species implicated in neurodegenerative disease.
PMN310
PMN310 targets toxic amyloid-beta oligomers while seeking to avoid binding monomers and plaque, potentially reducing off-target immune effects.
PRECISE-AD
The fully enrolled Phase 1b PRECISE-AD study evaluates PMN310 in patients with Alzheimer’s disease using safety, imaging, and biomarker measures.
Future catalysts
- Twelve-month unblinded topline results from the Phase 1b PRECISE-AD study of PMN310 in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ProMIS Neurosciences (PMN)?
ProMIS Neurosciences (PMN) most recently closed at 14.66 USD, a -1.35% move versus the previous session.
What is the market cap of ProMIS Neurosciences (PMN)?
ProMIS Neurosciences currently has a market capitalization of 91M USD on BioPharmSignal.
What does ProMIS Neurosciences do?
Misfolded Protein Therapeutics ProMIS Neurosciences develops antibodies that selectively recognize toxic misfolded protein species implicated in neurodegenerative disease. PMN310 PMN310 targets toxic amyloid-beta oligomers while seeking to avoid binding monomers and plaque, potentially reducing off-target immune effects. PRECISE-AD The fully enrolled Phase...
On which exchange is PMN stock listed?
ProMIS Neurosciences (PMN) is associated with NASDAQ, Canada and listed in the U, Biopharma.
What is PRECISE-AD?
Twelve-month unblinded topline results from the Phase 1b PRECISE-AD study of PMN310 in the first quarter of 2027.
Which conditions is ProMIS Neurosciences targeting with PRECISE-AD?
ProMIS Neurosciences is associated with neuroscience based on its company overview and current catalyst commentary.
How does ProMIS Neurosciences describe recent progress with PRECISE-AD?
Twelve-month unblinded topline results from the Phase 1b PRECISE-AD study of PMN310 in the first quarter of 2027.
What is Misfolded?
Misfolded Protein Therapeutics ProMIS Neurosciences develops antibodies that selectively recognize toxic misfolded protein species implicated in neurodegenerative disease.